WO2000072827A3 - Porous drug matrices and methods of manufacture thereof - Google Patents

Porous drug matrices and methods of manufacture thereof Download PDF

Info

Publication number
WO2000072827A3
WO2000072827A3 PCT/US2000/014578 US0014578W WO0072827A3 WO 2000072827 A3 WO2000072827 A3 WO 2000072827A3 US 0014578 W US0014578 W US 0014578W WO 0072827 A3 WO0072827 A3 WO 0072827A3
Authority
WO
WIPO (PCT)
Prior art keywords
drug
porous matrix
forming agent
pore forming
volatile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/014578
Other languages
French (fr)
Other versions
WO2000072827A9 (en
WO2000072827A2 (en
Inventor
Julie Straub
Howard Bernstein
Donald E Chickering Iii
Sarwat Khatak
Greg Randall
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acusphere Inc
Original Assignee
Acusphere Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27495210&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2000072827(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US09/433,486 external-priority patent/US6395300B1/en
Priority to EP00939365A priority Critical patent/EP1180020B2/en
Priority to CA002371836A priority patent/CA2371836C/en
Priority to IL14665900A priority patent/IL146659A0/en
Priority to BR0010984-3A priority patent/BR0010984A/en
Priority to HK03101310.8A priority patent/HK1048956B/en
Priority to DE60024811T priority patent/DE60024811T3/en
Priority to NZ516083A priority patent/NZ516083A/en
Application filed by Acusphere Inc filed Critical Acusphere Inc
Priority to DK00939365T priority patent/DK1180020T4/en
Priority to AU54459/00A priority patent/AU768022B2/en
Priority to MXPA01012106A priority patent/MXPA01012106A/en
Priority to AT00939365T priority patent/ATE312601T1/en
Priority to JP2000620939A priority patent/JP4722295B2/en
Publication of WO2000072827A2 publication Critical patent/WO2000072827A2/en
Publication of WO2000072827A3 publication Critical patent/WO2000072827A3/en
Priority to US09/798,824 priority patent/US6610317B2/en
Priority to IL146659A priority patent/IL146659A/en
Priority to NO20015753A priority patent/NO323761B1/en
Anticipated expiration legal-status Critical
Publication of WO2000072827A9 publication Critical patent/WO2000072827A9/en
Priority to US11/213,257 priority patent/USRE40493E1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Epoxy Compounds (AREA)

Abstract

Drugs, especially low aqueous solubility drugs, are provided in a porous matrix form, preferably microparticles, which enhances dissolution of the drug in aqueous media. The drug matrices preferably are made using a process that includes (i) dissolving a drug, preferably a drug having low aqueous solubility, in a volatile solvent to form a drug solution, (ii) combining at least one pore forming agent with the drug solution to form an emulsion, suspension, or second solutions, and (iii) removing the volatile solvent and pore forming agent from the emulsion, suspension, or second solution to yield the porous matrix of drug. The pore forming agent can be either a volatile liquid that is immiscible with the drug solvent or a volatile solid compound, preferably a volatile salt. In a preferred embodiment, spray drying is used to remove the solvents and the pore forming agent. The resulting porous matrix has a faster rate of dissolution following administration to a patient, as compared to non-porous matrix forms of the drug. In a preferred embodiment, microparticles of the porous drug matrix are reconstituted with an aqueous medium and administered parenterally, or processed using standard techniques into tablets or capsules for oral admisnistration. Paclitaxel or docetaxel can be provided in a porous matrix form, which allows the drug to be formulated without solubilizing agents and administered as a bolus. rocessed using standard techniques into tablets or capsules for oral administration. Paclitaxel or docetaxel can be provided in a porous matrix form, which allows the drug to be formulated without solubilizing agents and administered as a bolus.
PCT/US2000/014578 1999-05-27 2000-05-25 Porous drug matrices and methods of manufacture thereof Ceased WO2000072827A2 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
AU54459/00A AU768022B2 (en) 1999-05-27 2000-05-25 Porous drug matrices and methods of manufacture thereof
AT00939365T ATE312601T1 (en) 1999-05-27 2000-05-25 POROUS MEDICINAL MATRICES AND THEIR PRODUCTION PROCESS
MXPA01012106A MXPA01012106A (en) 1999-05-27 2000-05-25 Porous drug matrices and methods of manufacture thereof.
IL14665900A IL146659A0 (en) 1999-05-27 2000-05-25 Porous drug matrices and method of manufacture thereof
BR0010984-3A BR0010984A (en) 1999-05-27 2000-05-25 Porous drug matrices and processes for their manufacture
HK03101310.8A HK1048956B (en) 1999-05-27 2000-05-25 Porous drug matrices and methods of manufacture thereof
DE60024811T DE60024811T3 (en) 1999-05-27 2000-05-25 POROUS DRUG MATERIALS AND THEIR MANUFACTURING METHOD
NZ516083A NZ516083A (en) 1999-05-27 2000-05-25 Porous drug matrices and methods of manufacture thereof
CA002371836A CA2371836C (en) 1999-05-27 2000-05-25 Porous drug matrices and methods of manufacture thereof
DK00939365T DK1180020T4 (en) 1999-05-27 2000-05-25 Porous drug matrices and processes for their preparation
JP2000620939A JP4722295B2 (en) 1999-05-27 2000-05-25 Porous drug matrix and method for producing the same
EP00939365A EP1180020B2 (en) 1999-05-27 2000-05-25 Porous drug matrices and methods of manufacture thereof
US09/798,824 US6610317B2 (en) 1999-05-27 2001-03-02 Porous paclitaxel matrices and methods of manufacture thereof
IL146659A IL146659A (en) 1999-05-27 2001-11-21 Methods for preparing a porous matrix of drug
NO20015753A NO323761B1 (en) 1999-05-27 2001-11-26 Process for the preparation of a porous matrix of drug and pharmaceutical composition comprising it.
US11/213,257 USRE40493E1 (en) 1999-05-27 2005-08-26 Porous paclitaxel matrices and methods of manufacture thereof

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US13632399P 1999-05-27 1999-05-27
US60/136,323 1999-05-27
US15865999P 1999-10-08 1999-10-08
US60/158,659 1999-10-08
US09/433,486 1999-11-04
US09/433,486 US6395300B1 (en) 1999-05-27 1999-11-04 Porous drug matrices and methods of manufacture thereof
US18631000P 2000-03-02 2000-03-02
US60/186,310 2000-03-02

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/798,824 Continuation US6610317B2 (en) 1999-05-27 2001-03-02 Porous paclitaxel matrices and methods of manufacture thereof

Publications (3)

Publication Number Publication Date
WO2000072827A2 WO2000072827A2 (en) 2000-12-07
WO2000072827A3 true WO2000072827A3 (en) 2001-01-25
WO2000072827A9 WO2000072827A9 (en) 2002-01-31

Family

ID=27495210

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/014578 Ceased WO2000072827A2 (en) 1999-05-27 2000-05-25 Porous drug matrices and methods of manufacture thereof

Country Status (18)

Country Link
EP (1) EP1180020B2 (en)
JP (1) JP4722295B2 (en)
KR (2) KR100883477B1 (en)
CN (1) CN1240373C (en)
AT (1) ATE312601T1 (en)
AU (1) AU768022B2 (en)
BR (1) BR0010984A (en)
CA (1) CA2371836C (en)
DE (1) DE60024811T3 (en)
DK (1) DK1180020T4 (en)
ES (1) ES2250141T5 (en)
HK (1) HK1048956B (en)
IL (2) IL146659A0 (en)
MX (1) MXPA01012106A (en)
NO (1) NO323761B1 (en)
NZ (1) NZ516083A (en)
TW (1) TWI274589B (en)
WO (1) WO2000072827A2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7276246B2 (en) 2003-05-09 2007-10-02 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
US7306812B2 (en) 2003-05-09 2007-12-11 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
US7879358B2 (en) 2002-03-20 2011-02-01 Alkermes, Inc. Pulmonary delivery for levodopa
US8852623B2 (en) 2003-03-31 2014-10-07 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of dopamine agonist

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6342533B1 (en) 1998-12-01 2002-01-29 Sepracor, Inc. Derivatives of (−)-venlafaxine and methods of preparing and using the same
HUP0200898A3 (en) 1999-04-06 2005-09-28 Sepracor Inc Derivatives of venlafaxine and methods of preparing and using the same
US8771740B2 (en) * 1999-12-20 2014-07-08 Nicholas J. Kerkhof Process for producing nanoparticles by spray drying
US7473433B2 (en) 2000-12-21 2009-01-06 Nektar Therapeutics Pulmonary delivery of polyene antifungal agents
MY120279A (en) 2000-05-26 2005-09-30 Pharmacia Corp Use of a celecoxib composition for fast pain relief
US6589557B2 (en) * 2000-06-15 2003-07-08 Acusphere, Inc. Porous celecoxib matrices and methods of manufacture thereof
US6613308B2 (en) * 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US6514482B1 (en) 2000-09-19 2003-02-04 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
DE10059020A1 (en) 2000-11-28 2002-05-29 Gruenenthal Gmbh Dosage forms that can be administered parenterally
MXPA03006404A (en) * 2001-01-18 2004-12-02 Upjohn Co PACLITAXEL MICROEMULSION CHEMOTHERAPEUTIC COMPOSITIONS WITH IMPROVED ORAL BIODISPONIBILITY.
US7115565B2 (en) 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
EP2319826A1 (en) † 2001-02-12 2011-05-11 Wyeth LLC Succinate salt of O-desmethyl-venlafaxin
US7090830B2 (en) 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
WO2002094231A1 (en) * 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of analgesics through an inhalation route
US7585493B2 (en) 2001-05-24 2009-09-08 Alexza Pharmaceuticals, Inc. Thin-film drug delivery article and method of use
US6805853B2 (en) 2001-11-09 2004-10-19 Alexza Molecular Delivery Corporation Delivery of diazepam through an inhalation route
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
JP2005503425A (en) 2001-05-24 2005-02-03 アレックザ モレキュラー デリヴァリー コーポレイション Delivery of drug ester by the prescribed inhalation route
WO2003007968A1 (en) * 2001-07-17 2003-01-30 Sun Pharmaceutical Industries Ltd. A cardiotonic composition
US7005138B2 (en) * 2001-12-21 2006-02-28 Duramed Pharmaceuticals, Inc. Method of systematically delivering SSRIs
JP4452970B2 (en) 2002-03-27 2010-04-21 日本臓器製薬株式会社 Diclofenac sodium oral formulation
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US9060941B2 (en) 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US8980870B2 (en) 2002-09-24 2015-03-17 Boehringer Ingelheim International Gmbh Solid telmisartan pharmaceutical formulations
CA2500065A1 (en) * 2002-09-30 2004-04-15 Acusphere, Inc. Sustained release porous microparticles for inhalation
US20040234699A1 (en) 2003-05-21 2004-11-25 Alexza Molecular Delivery Corporation Methods of controlling uniformity of substrate temperature and self-contained heating unit and drug-supply unit employing same
GB0401947D0 (en) 2004-01-28 2004-03-03 Unilever Plc Porous bodies and method of production thereof
KR100681660B1 (en) * 2004-03-17 2007-02-09 주식회사종근당 Pharmaceutical Compositions of Release Control Pellets
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
EP2246086A3 (en) 2004-08-12 2012-11-21 Alexza Pharmaceuticals, Inc. Aerosol drug delivery device incorporating percussively activated heating unit
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
EP1681056A1 (en) * 2005-01-14 2006-07-19 Krka Tovarna Zdravil, D.D., Novo Mesto Process for preparing lansoprazole
AU2006264407B2 (en) * 2005-07-04 2012-08-30 Ramu Krishnan Improved drug or pharmaceutical compounds and a preparation thereof
GB0517688D0 (en) * 2005-08-31 2005-10-05 Cambridge Biostability Ltd Improvements in the stabilisation of biological materials
GB0523638D0 (en) 2005-11-21 2005-12-28 Cambridge Biostability Ltd Pharmaceutical device for the administration of substances to patients
AR054215A1 (en) * 2006-01-20 2007-06-13 Eriochem Sa A PHARMACEUTICAL FORMULATION OF A TAXANE, A SOLID COMPOSITION OF A LIOFILIZED TAXAN FROM AN ACETIC ACID SOLUTION, A PROCEDURE FOR THE PREPARATION OF A SOLID COMPOSITION OF A TAXANE, A SOLUBILIZING COMPOSITION OF A LIOFILIZED TAXANE AND AN ELEMENTARY KIT
AU2007208998A1 (en) * 2006-01-27 2007-08-02 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin A method of producing porous microparticles
KR100917809B1 (en) * 2006-05-22 2009-09-18 에스케이케미칼주식회사 Stable Pharmaceutical Composition containing Docetaxel
GB0613925D0 (en) 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
EP2121088B1 (en) 2007-03-09 2016-07-13 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
BRPI0810606B1 (en) 2007-04-27 2018-10-16 Endo Pharmaceuticals Solutions implant device and process for its preparation
PT103743B (en) * 2007-05-16 2013-01-15 Hovione Farmaciencia S A PROCESS FOR PREPARING DERIVATIVES OF 21-DISODIUM PHOSPHATE OF PREGNANOS.
GB0716591D0 (en) * 2007-08-24 2007-10-03 Vereniging Het Nl Kanker I Composition
MX2010002179A (en) 2007-08-24 2010-04-27 Stichting Het Nl Kanker I Composition.
MX2010003923A (en) * 2007-10-09 2010-05-05 Novartis Ag Pharmaceutical formulation of valsartan.
US9801818B2 (en) 2007-12-31 2017-10-31 Samyang Biopharmaceuticals Corporation Method for stabilizing amphiphilic block copolymer micelle composition containing poorly water-soluble drug
KR101024742B1 (en) * 2007-12-31 2011-03-24 주식회사 삼양사 Taxane-containing amphiphilic block copolymer micelle composition and preparation method thereof
US20110206770A1 (en) * 2008-07-25 2011-08-25 Alphapharm Pty. Ltd. Atovaquone with a particle size diameter range (d90) of greater than 3 microns to about 10 microns
JP2012500788A (en) * 2008-08-22 2012-01-12 スティヒティング ヘット ネーデルランド カンケル インスティテュート Composition
WO2010102066A1 (en) 2009-03-05 2010-09-10 Bend Research, Inc. Dextran polymer powder for inhalation administration of pharmaceuticals
WO2010111132A2 (en) 2009-03-27 2010-09-30 Bend Research, Inc. Spray-drying process
PT2611530T (en) 2010-09-03 2019-05-09 Bend Res Inc Spray-drying apparatus and methods of using the same
EP2611529B1 (en) 2010-09-03 2019-01-23 Bend Research, Inc. Spray-drying method
EP2618924A1 (en) 2010-09-24 2013-07-31 Bend Research, Inc. High-temperature spray drying process and apparatus
WO2012114342A1 (en) 2011-02-23 2012-08-30 Coeruleus Ltd. Flumazenil complexes, compositions comprising same and uses thereof
US9060938B2 (en) 2011-05-10 2015-06-23 Bend Research, Inc. Pharmaceutical compositions of active agents and cationic dextran polymer derivatives
CN103301095B (en) * 2012-03-13 2016-04-13 中国科学院上海药物研究所 The composite drug-loaded composition and method of making the same of a kind of porous for improving probucol oral absorption
US20150150788A1 (en) * 2012-06-22 2015-06-04 The University Of Queensland Method and composition for delivering a compound through a biological barrier
EP3082428A4 (en) 2013-12-09 2017-08-02 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
EP3154528B1 (en) 2014-06-11 2023-04-05 SpecGx LLC Spray dried compositions having different dissolution profiles and processes for their preparation
EP3212169B1 (en) 2014-10-31 2021-01-13 Bend Research, Inc. Process for forming active domains dispersed in a matrix
CA2971440C (en) * 2014-12-18 2024-02-13 Windgap Medical, Inc. Method and compositions for dissolving or solubilizing therapeutic agents
JP6921759B2 (en) 2015-06-04 2021-08-18 クリティテック・インコーポレイテッド Collection device and usage
AU2016323770A1 (en) 2015-09-16 2018-03-29 Dfb Soria, Llc Delivery of drug nanoparticles and methods of use thereof
SG10201913409VA (en) 2016-04-04 2020-03-30 Crititech Inc Methods for solid tumor treatment
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
KR101965708B1 (en) * 2016-08-30 2019-04-04 이화여자대학교 산학협력단 Sponge-like porous microspheres and method for preparing the same
JP2020514359A (en) 2017-03-15 2020-05-21 ディーエフビー ソリア リミテッド ライアビリティ カンパニー Topical therapy for the treatment of cutaneous malignancies using taxane nanoparticles
SG11201909840TA (en) 2017-06-09 2019-11-28 Crititech Inc Treatment of epithelial cysts by intracystic injection of antineoplastic particles
CN115919815A (en) 2017-06-14 2023-04-07 克里蒂泰克公司 Methods of treating pulmonary diseases
KR20200064112A (en) 2017-10-03 2020-06-05 크리티테크, 인크. Local delivery of anti-neoplastic particles in combination with systemic delivery of immunotherapeutics for the treatment of cancer
US11278492B2 (en) 2018-01-05 2022-03-22 Impel Neuropharma, Inc. Intranasal delivery of olanzapine by precision olfactory device
US12214118B2 (en) 2018-02-02 2025-02-04 Alexza Pharmaceuticals, Inc. Electrical condensation aerosol device
KR20200132963A (en) 2018-03-16 2020-11-25 디에프비 소리아, 엘엘씨 Topical therapy for the treatment of cervical intraepithelial neoplasia (CIN) and cervical cancer using taxane nanoparticles
MX2021009038A (en) 2019-01-29 2021-08-16 Bayer Healthcare Llc Topical gel compositions of naproxen.
WO2020227816A1 (en) * 2019-05-10 2020-11-19 Anomera Inc. Porous cellulose microparticles and methods of manufacture thereof
PT4037666T (en) 2020-12-08 2024-06-25 Ruminant Biotech Corp Ltd Improvements to devices and methods for delivery of substances to animals
CN113081971A (en) * 2021-05-14 2021-07-09 江西中医药大学 Traditional Chinese medicine porous core-shell type composite particle powder and preparation method and application thereof
CN117538462B (en) * 2024-01-10 2024-03-26 地奥集团成都药业股份有限公司 Method for detecting related substances of amlodipine benazepril capsules

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1265615A (en) * 1970-09-10 1972-03-01
DE3713326A1 (en) * 1986-04-25 1987-10-29 Basf Ag Spray-dried active substance granules and their preparation
EP0655237A1 (en) * 1993-11-27 1995-05-31 Hoechst Aktiengesellschaft Medicinal aerosol formulation
WO1998031346A1 (en) * 1997-01-16 1998-07-23 Massachusetts Institute Of Technology Preparation of particles for inhalation
WO1999056731A1 (en) * 1998-04-30 1999-11-11 Acusphere, Inc. Matrices formed of polymer and hydrophobic compounds for use in drug delivery

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7313626A (en) † 1973-10-04 1975-04-08 Philips Nv COMBINED DEVICE FOR THE PRODUCTION AND SELLING OF HEAT WITH A HEAT CONNECTED DEVICE.
GB8322007D0 (en) † 1983-08-16 1983-09-21 Wellcome Found Pharmaceutical delivery system
US5762961A (en) * 1996-02-09 1998-06-09 Quadrant Holdings Cambridge Ltd. Rapidly soluble oral solid dosage forms, methods of making same, and compositions thereof
DE69813853T3 (en) * 1997-09-29 2011-05-12 Novartis Ag PERFORATED MICROTEILS AND THEIR USE
JP4758525B2 (en) * 1998-03-20 2011-08-31 武田薬品工業株式会社 Sustained release preparation of bioactive polypeptide and method for producing the same

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1265615A (en) * 1970-09-10 1972-03-01
DE3713326A1 (en) * 1986-04-25 1987-10-29 Basf Ag Spray-dried active substance granules and their preparation
EP0655237A1 (en) * 1993-11-27 1995-05-31 Hoechst Aktiengesellschaft Medicinal aerosol formulation
WO1998031346A1 (en) * 1997-01-16 1998-07-23 Massachusetts Institute Of Technology Preparation of particles for inhalation
WO1999056731A1 (en) * 1998-04-30 1999-11-11 Acusphere, Inc. Matrices formed of polymer and hydrophobic compounds for use in drug delivery

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7879358B2 (en) 2002-03-20 2011-02-01 Alkermes, Inc. Pulmonary delivery for levodopa
USRE43711E1 (en) 2002-03-20 2012-10-02 Civitas Therapeutics, Inc. Pulmonary delivery for levodopa
US8852623B2 (en) 2003-03-31 2014-10-07 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of dopamine agonist
US9278163B2 (en) 2003-03-31 2016-03-08 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of dopamine agonist
US7276246B2 (en) 2003-05-09 2007-10-02 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
US7306812B2 (en) 2003-05-09 2007-12-11 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device

Also Published As

Publication number Publication date
DK1180020T4 (en) 2009-10-05
DE60024811T2 (en) 2006-09-14
EP1180020B2 (en) 2009-06-24
IL146659A0 (en) 2002-07-25
ES2250141T3 (en) 2006-04-16
NO323761B1 (en) 2007-07-02
NO20015753L (en) 2002-01-28
NZ516083A (en) 2003-08-29
IL146659A (en) 2010-05-31
KR100752000B1 (en) 2007-08-28
CA2371836C (en) 2006-01-31
JP4722295B2 (en) 2011-07-13
DE60024811T3 (en) 2010-01-07
AU5445900A (en) 2000-12-18
DE60024811D1 (en) 2006-01-19
KR100883477B1 (en) 2009-02-16
BR0010984A (en) 2002-04-30
WO2000072827A9 (en) 2002-01-31
HK1048956A1 (en) 2003-04-25
CN1240373C (en) 2006-02-08
CA2371836A1 (en) 2000-12-07
ATE312601T1 (en) 2005-12-15
EP1180020B1 (en) 2005-12-14
TWI274589B (en) 2007-03-01
KR20020011992A (en) 2002-02-09
CN1365274A (en) 2002-08-21
HK1094775A1 (en) 2007-04-13
EP1180020A2 (en) 2002-02-20
WO2000072827A2 (en) 2000-12-07
AU768022B2 (en) 2003-11-27
ES2250141T5 (en) 2009-11-05
JP2003500438A (en) 2003-01-07
NO20015753D0 (en) 2001-11-26
KR20070069219A (en) 2007-07-02
DK1180020T3 (en) 2006-03-27
HK1048956B (en) 2006-07-28
MXPA01012106A (en) 2003-06-30

Similar Documents

Publication Publication Date Title
CA2371836A1 (en) Porous drug matrices and methods of manufacture thereof
RU2420290C2 (en) Hard, suitable for oral intake pharmaceutical forms of application, containing rivaroxaban with modified release
AU2002222567B2 (en) Composition improved in solubility or oral absorbability
JP2820239B2 (en) Controlled release powder and its production
WO2001095877A3 (en) Porous celecoxib matrices and methods of manufacture thereof
JP2000229846A (en) Release control type dosage form
JP2007182449A (en) Method for producing pharmaceutical composition
CN120091810A (en) Methods and highly bioavailable permeable compounds for treating viral diseases
JP2000256195A (en) Nifedipine pill and preparation of nifedipine pill
JP4401778B2 (en) Method for producing a substance by reacting an active substance with a porous support using a supercritical fluid
KR100583065B1 (en) Programmed and pulsed release multi-part pharmaceutical formulations and methods of making the same
JPS58116414A (en) Composition for pharmaceutical of prolonged release containing nicardipine and preparation thereof
AU2003235156B2 (en) Solid dispersion composition
HU205851B (en) Systhem of regulated release of the active components and process for producing it
JPS6153214A (en) Novel composition
DK164019B (en) STABILIZED LIQUID PHARMACEUTICAL COMPOSITION CONTAINING IONIC MEDICINES WITH PROTRAHERED EFFECTS AND PROCEDURES FOR THE PRODUCTION THEREOF
Minocha et al. SOlubility enhancement of poorly water soluble drugs by various techniques
KR100981750B1 (en) Spray-dried granules and preparation method thereof
JP2005298472A (en) Composition for oral administration containing itraconazole
CN100333729C (en) Breviscapine permeation pump control release preparation
WO2007064084A1 (en) Granules containing pranlukast and processes for the preparation thereof
EP0323762B1 (en) Antitussive compositions and their preparation
JPH06128147A (en) Method for improving solubility of poorly water-soluble chemicals and chemical composition obtained thereby
OGiso et al. ABSORPTION AND BIOAVAILABILITY OF CALCIUM AND MAGNESIUM SALTS OF INDOMETHACIN FROM RECTAL SUPPOSITO-RIES
EP0971701B1 (en) Method for removing high boiling solvents from drug formulations by vacuum drying

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 00808161.1

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 09798824

Country of ref document: US

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2371836

Country of ref document: CA

Ref document number: 2371836

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020017015052

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 54459/00

Country of ref document: AU

Ref document number: PA/a/2001/012106

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2000 620939

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2000939365

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 516083

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2001/10347

Country of ref document: ZA

Ref document number: 200110347

Country of ref document: ZA

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/5-5/5, DRAWINGS, REPLACED BY NEW PAGES 1/5-5/5; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWP Wipo information: published in national office

Ref document number: 1020017015052

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2000939365

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 54459/00

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 2000939365

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1020017015052

Country of ref document: KR